AIDS Meds: Founded & Operated by People with HIVPOZ logo
Back to home » Treatment News » Top Stories

emailrssprint

Leishmaniasis Drug Stimulates HIV Replication

January 30, 2007

By David Douglas

(Reuters Health) - A widely employed anti-leishmaniasis agent can promote HIV replication in human cells and tissue, Canadian researchers report in the January 15th issue of the Journal of Infectious Diseases.

"Altogether," lead investigator Dr. Michel J. Tremblay told Reuters Health, "our data demonstrate that one of the most commonly used compounds for the treatment of leishmaniasis, the antimonial drug sodium stibogluconate, can enhance HIV-1 replication in CD4+ T lymphocytes and lymphoid tissue, which are recognized as natural reservoirs of this pathogen."

Dr. Tremblay and colleagues at University Laval, Quebec note that the agent acts as an inhibitor of phosphotyrosyl phosphatases and such inhibitors can promote HIV-1 replication.

As he mentioned, the team found that the compound indeed induced an increase in HIV-1 transcription and virus replication in primary CD4+ T cells and thymic histocultures.

Leishmaniasis is an important opportunistic disease in HIV patients, and Dr. Tremblay noted that "the use of sodium stibogluconate to control parasitemia in patients dually infected with leishmania and HIV-1 should thus be envisaged with caution."

"Such dually infected patients," he concluded, "should be treated with effective antiparasitic agents to avoid a possible leishmania-mediated amplification of HIV-1 production and subsequent deterioration of their immunological status."

[Note from AIDSmeds: Leishmaniasis is spread by the bite of infected sand flies in various tropical and sub-tropical countries. More than 90% of the world's cases of leishmaniasis are in India, Bangladesh, Nepal, Sudan, and Brazil. Cases of leishmaniasis, acquired in the United States, are very rare. Sodium stibogluconate is an intravenous medication better known by its brand name, Pentostam®]   

J Infect Dis 2007;195:236-245.



Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

emailrssprint



[Go to top]



Most Popular Stories

CD4s Predictive of Non-AIDS-Related Health Problems

HIV Immunotherapy Shows Promise

Slim for Summer: Safe and Sane Weight Loss

Hetero Men Also at Risk for Anal HPV

Treatment Failure: Symptoms Matter Too

Interfering with Immune Protein Slows HIV Reproduction


Most Popular Lessons

Herpes Simplex Virus

Syphilis & Neurosyphilis

Shingles

The HIV Life Cycle

Human Papilloma Virus (HPV)

What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Treatment News Archive

May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006


© 2008 Smart + Strong. All Rights Reserved. terms of use and your privacy